12 Oct 2022 --- Danish bioscience company Chr. Hansen has closed its financial year with 9% organic growth driven mainly by volume growth. Revenue increased by 13%, amounting to €1.218 billion (US$1.183 billion). “We have delivered a solid financial performance despite a volatile macroeconomic and geopolitical environment. Organic growth reached 9%, EBIT margin 26.8%, and the free cash flow ended at €172 million (US$167 million) in line with our latest guidance,” says Mauricio Graber, CEO at Chr. Hansen.
